Cumberland Pharmaceuticals (CPIX) EBT Margin (2010 - 2026)

Cumberland Pharmaceuticals has disclosed EBT Margin across 17 years of filings, most recently posting 34.36% for Q1 2026.

• EBT Margin for Q1 2026 came in at 34.36%, down 4506.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 17.17% (down 909.0% YoY), and the FY2025 annual result was 6.31%, up 1076.0% from the prior year.
• EBT Margin came in at 34.36% for Q1 2026 at Cumberland Pharmaceuticals, down from 10.18% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 10.7% in Q1 2025 to a low of 67.11% in Q4 2023.
• The 5-year median for EBT Margin is 12.49% (2022), against an average of 15.08%.
• Across the five-year window, EBT Margin jumped 4834 bps in 2024 and sank 4506 bps in 2026, its largest moves.
• Cumberland Pharmaceuticals' EBT Margin stood at 26.43% in 2022, then sank by 154 bps to 67.11% in 2023, then surged by 72 bps to 18.77% in 2024, then jumped by 46 bps to 10.18% in 2025, then sank by 238 bps to 34.36% in 2026.
• The last three EBT Margin figures came in at 34.36% (Q1 2026), 10.18% (Q4 2025), and 23.44% (Q3 2025), per Business Quant data.